ALMS
Price
$7.10
Change
-$0.19 (-2.61%)
Updated
Sep 25 closing price
Capitalization
947.82M
46 days until earnings call
Intraday BUY SELL Signals
DRUG
Price
$51.80
Change
-$1.71 (-3.20%)
Updated
Sep 25 closing price
Capitalization
512.68M
Intraday BUY SELL Signals
Interact to see
Advertisement

ALMS vs DRUG

ALMS vs DRUG Comparison Chart in %
View a ticker or compare two or three
VS
ALMS vs. DRUG commentary
Sep 28, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALMS is a Hold and DRUG is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
TECHNICAL ANALYSIS
Technical Analysis
ALMSDRUG
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
N/A
Bearish Trend 6 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 5 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
COMPARISON
Comparison
Sep 28, 2026
Stock price -- (ALMS: $7.10 vs. DRUG: $51.80)
Brand notoriety: ALMS and DRUG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALMS: 64% vs. DRUG: 122%
Market capitalization -- ALMS: $947.82M vs. DRUG: $512.68M
ALMS [@Biotechnology] is valued at $947.82M. DRUG’s [@Biotechnology] market capitalization is $512.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALMS’s FA Score shows that 1 FA rating(s) are green while DRUG’s FA Score has 1 green FA rating(s).

  • ALMS’s FA Score: 1 green, 4 red.
  • DRUG’s FA Score: 1 green, 4 red.
According to our system of comparison, ALMS is a better buy in the long-term than DRUG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALMS’s TA Score shows that 5 TA indicator(s) are bullish while DRUG’s TA Score has 3 bullish TA indicator(s).

  • ALMS’s TA Score: 5 bullish, 2 bearish.
  • DRUG’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ALMS is a better buy in the short-term than DRUG.

Price Growth

ALMS (@Biotechnology) experienced а -8.62% price change this week, while DRUG (@Biotechnology) price change was -15.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.17%. For the same industry, the average monthly price growth was -13.24%, and the average quarterly price growth was +5.35%.

Reported Earning Dates

ALMS is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ALMS
Daily Signal:
Gain/Loss:
DRUG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SHG80.951.36
+1.71%
Shinhan Financial Group Co Ltd
TNXP9.860.16
+1.65%
Tonix Pharmaceuticals Holding Corp
CATY61.450.32
+0.52%
Cathay General Bancorp
PUBM18.600.05
+0.27%
PubMatic
IQST0.99-0.01
-1.19%
iQSTEL Inc.